tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

NRIX Stock Latest News

Nurix Therapeutics price target raised to $34 from $31 at JPMorgan
The FlyNurix Therapeutics price target raised to $34 from $31 at JPMorgan
12d ago
NRIX
Nurix Therapeutics price target raised to $31 from $20 at Barclays
PremiumThe Fly
Nurix Therapeutics price target raised to $31 from $20 at Barclays
12d ago
NRIX
Nurix Therapeutics price target raised to $15 from $14 at Morgan Stanley
PremiumThe Fly
Nurix Therapeutics price target raised to $15 from $14 at Morgan Stanley
13d ago
NRIX
Investor interest in Nurix Therapeutics keeps climbing, says Oppenheimer
PremiumThe Fly
Investor interest in Nurix Therapeutics keeps climbing, says Oppenheimer
14d ago
NRIX
Nurix Therapeutics price target raised to $27 from $26 at RBC Capital
PremiumThe Fly
Nurix Therapeutics price target raised to $27 from $26 at RBC Capital
15d ago
NRIX
Nurix Therapeutics price target lowered to $29 from $31 at Needham
PremiumThe FlyNurix Therapeutics price target lowered to $29 from $31 at Needham
15d ago
NRIX
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
PremiumPress Releases
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
15d ago
NRIX
Nurix Therapeutics reports Q2 EPS (71c), consensus (63c)
PremiumThe Fly
Nurix Therapeutics reports Q2 EPS (71c), consensus (63c)
15d ago
NRIX
Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
PremiumPress Releases
Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
19d ago
NRIX
Is NRIX a Buy, Before Earnings?
PremiumPre-Earnings
Is NRIX a Buy, Before Earnings?
19d ago
NRIX
Nurix Therapeutics price target raised to $26 from $23 at RBC Capital
PremiumThe Fly
Nurix Therapeutics price target raised to $26 from $23 at RBC Capital
30d ago
NRIX
Nurix Therapeutics price target raised to $26 from $19 at H.C. Wainwright
PremiumThe Fly
Nurix Therapeutics price target raised to $26 from $19 at H.C. Wainwright
1M ago
NRIX
Nurix Therapeutics management to meet with Piper Sandler
PremiumThe FlyNurix Therapeutics management to meet with Piper Sandler
1M ago
NRIX
Nurix Therapeutics Reports Promising NX-5948 Trial Results
PremiumCompany Announcements
Nurix Therapeutics Reports Promising NX-5948 Trial Results
1M ago
8K
NRIX
Nurix Therapeutics presents results from ongoing NX-5948 trial
PremiumThe Fly
Nurix Therapeutics presents results from ongoing NX-5948 trial
1M ago
NRIX
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
PremiumPress Releases
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
1M ago
NRIX
Nurix Therapeutics files automatic mixed securities shelf
PremiumThe Fly
Nurix Therapeutics files automatic mixed securities shelf
2M ago
NRIX
Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
PremiumPress Releases
Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
2M ago
NRIX
Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
PremiumPress Releases
Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
2M ago
NRIX
Nurix Therapeutics appoints O’Connor as CMO, Phiasivongsa as CTO
PremiumThe FlyNurix Therapeutics appoints O’Connor as CMO, Phiasivongsa as CTO
2M ago
NRIX
Nurix Therapeutics Announces Board Chair Transition
PremiumPress Releases
Nurix Therapeutics Announces Board Chair Transition
2M ago
NRIX
Nurix Therapeutics chairman David Lacey steps down, Julia Gregory succeeds
PremiumThe Fly
Nurix Therapeutics chairman David Lacey steps down, Julia Gregory succeeds
2M ago
NRIX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >